Review of miglustat for clinical management in Gaucher disease type I

62Citations
Citations of this article
80Readers
Mendeley users who have this article in their library.

Abstract

Gaucher disease is a progressive lysosomal storage disorder caused by the deficiency of glucocerebrosidase, and characterized by intralysosomal storage of glucosylceramide that leads to dysfunction in multiple organ systems. Intravenous enzyme replacement with imiglucerase is the accepted standard for treatment of symptomatic patients and has been effective in reducing many of the signs and symptoms of type I Gaucher disease in the majority of patients without serious adverse effects. An alternative therapeutic approach is substrate reduction therapy with N-butyldeoxynojirimycin (NB-DNJ) (miglustat; Zavesca®), an imino sugar that reversibly inhibits glucosylceremide synthase and reduces intracellular storage of glucosylceramide. Miglustat was recently approved in Europe and the United States for symptomatic patients with mild to moderate clinical manifestations for whom enzyme replacement therapy is not an option. This review article discusses the results of clinical studies and use of miglustat as a therapeutic agent in patients with type I Gaucher disease. © 2008 Dove Medical Press Limited. All rights reserved.

References Powered by Scopus

Replacement therapy for inherited enzyme deficiency — macrophage-targeted glucocerebrosidase for gaucher's disease

1180Citations
N/AReaders
Get full text

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis

700Citations
N/AReaders
Get full text

Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study

518Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Iminosugars: from botanical curiosities to licensed drugs

184Citations
N/AReaders
Get full text

Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group

131Citations
N/AReaders
Get full text

Therapy for lysosomal storage disorders

126Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ficicioglu, C. (2008). Review of miglustat for clinical management in Gaucher disease type I. Therapeutics and Clinical Risk Management. https://doi.org/10.2147/tcrm.s6865

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 27

77%

Researcher 7

20%

Professor / Associate Prof. 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 14

33%

Agricultural and Biological Sciences 12

28%

Biochemistry, Genetics and Molecular Bi... 9

21%

Pharmacology, Toxicology and Pharmaceut... 8

19%

Save time finding and organizing research with Mendeley

Sign up for free